What does three-times Tour de France winner, an animation agency and a medical device all have in common? Five awards and screening at the ‘17th Annual Bicycle Film Festival’ in New York, it seems.
Having recently emerged from receiving the Honouree Award at The Webby Awards – dubbed by New York Times as ‘the highest honour of the internet’, the animation ‘Y3llow’ will light up the screens at this year’s ‘Bicycle Film Festival’ on 20-25th June 2017. Y3llow is an animated collaboration between Rhinomed, Turbine, Jumbla and three-time Tour de France champion Chris Froome.
Turbine, the breathing device used by Froome, is developed by Melbourne technology company Rhinomed Ltd. While it has been adopted by leading athletes for their training, racing and recovery; everyday exercisers are now finding that the benefits extend in ways they hadn’t recognised.
“For me, I find the biggest benefit of the Turbine in the time trial stages and that whole build up to the warm-ups … Just for me to really focus on my breathing – get the maximum amount of airflow possible…and really just to calm my nerves,” relates Froome.
During exercise, people tend to breathe through their mouths, pushing the cold, dry air directly to the lungs, meaning that the air is moistened to only 60-70% relative humidity. Nose-breathing, helps to maximise the intake of warm, filtered and humidified air – taking it to about 80 to 90% humidity(1).
Part of the research and development behind Turbine shows its ability to support and improve nasal breathing. Clinically proven to increase airflow through the nose by an average of 38%(2), Turbine is individually adjustable, making it available for people to use with deviated septums or obstructed nasal passages.
As Froome relates in the video: “The Yellow Jersey represents pain and sacrifice in the present, for a legacy that lasts forever. You earn the shine of the Yellow Jersey in the darkest hours of training.”
1 Web mD – http://www.webmd.com/asthma/features/athletes-guide-exercise-induced-asthma
2 Royal Victorian Ear and Eye Hospital (2003) Phase 1 ‘Proof of Principle’ randomised cross-over study of the effect of a new therapeutic device and a marketed device on nasal airflow rates in normal, healthy adults’. Protocol number: ASAP 1-03, August 2003.